Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipatasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 known ✓ | Q9Y243 | 20/20 | 1.00 |
| ▸ | AKT1 known ✓ | P31749 | 19/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 19/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | PRKG1 | Q13976 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipatasertib SCHEMBL191659 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL31658211 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL29881570 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL29356998 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL17424852 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191491 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191495 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191492 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191496 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL27128127 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220113311-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-04-14 | — | — | US | disclosed |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3877511-A1 | EXPANSION OF TILS UTILIZING AKT PATHWAY INHIBITORS | Iovance Biotherapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2018031407-A1 | METHODS OF DETECTING AND TREATING A TUMOR EXPRESSING PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220113311-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | PDK1, PDK2, PCK2 | AKT3 257/4885AKT1 439/4885AKT2 335/4885 |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | PDK1, PDK2, PCK2 | AKT3 257/4885AKT1 439/4885AKT2 335/4885 |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | PDK1, PDK2, PCK2 | AKT3 257/4885AKT1 439/4885AKT2 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.